

SYNGENTA AG
Form 6-K
November 13, 2012

FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of November 2012

Commission File Number: 001-15152

SYNGENTA AG
(Translation of registrant's name into English)

Schwarzwaldallee 215
4058 Basel
Switzerland
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form X	Form
20-F	40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No X

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No X

Indicate by check mark whether by furnishing the information contained in this Form, the Registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes No X

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

Re: SYNGENTA AG
Disclosure: “Syngenta secures EU approval for next generation fungicide”

Herewith we furnish a press release related to Syngenta AG. The full text of the press release is the following

###

Syngenta International AG	Media contacts:	Analyst/Investor contacts:
Media Office CH-4002 Basel Switzerland Tel: +41 61 323 2323 Fax: +41 61 323 2424 www.syngenta.com	Paul Barrett Switzerland +41 61 323 2323 Daniel Braxton Switzerland +41 61 323 2323	Jennifer Gough Switzerland +41 61 323 5059 USA +1 202 737 6521 Lars Oestergaard Switzerland +41 61 323 6793 USA +1 202 737 6520

Basel, Switzerland, November 13, 2012

Syngenta secures EU approval for next generation fungicide

- Isopyrazam sets new standard in disease control
- Consistent crop yield enhancement
- Product registrations across multiple crops planned

Syngenta today announced that it has received European Union (EU) approval for isopyrazam, the first active ingredient from its strong pipeline of next generation fungicides. Approval represents a major step forward in the control of a wide spectrum of damaging fungal diseases, including best-in-class performance against Yellow Rust.

Isopyrazam's advanced "double-binding" technology ensures strong adhesion to fungus and to leaf wax, providing long-lasting and durable disease protection.

Under the EU's provisional approval system, British and Irish cereal farmers have for the past two growing seasons experienced the benefits of isopyrazam, which is marketed as **SEGURIS™** in wheat and **BONTIMA™** in barley. These growers have consistently achieved better disease control, which has helped deliver higher crop yields: **SEGURIS** treatments increase yield by up to two tonnes per hectare versus current chemistries.

John Atkin, Chief Operating Officer, said: "Breakthrough chemical innovation is an enduring part of our integrated strategy. Isopyrazam sets the highest standards for disease control and yield response and this approval means growers throughout the EU can now benefit from this important addition to our portfolio."

Syngenta intends to register a range of products containing isopyrazam in major EU markets for use on cereals and others crops such as oilseed rape, vegetables and pome fruits.

Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.

Syngenta – November 13, 2012 / Page 2 of 2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SYNGENTA AG

Date: November 13, 2012

By: /s/ Dr. Tobias Meili
Name: Dr. Tobias Meili
Title: Head Corporate Legal
Affairs

By: /s/ Brigitte Benz
Name: Brigitte Benz
Title: Head Shareholder Services &
Group Administration
